Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Place in treatment, anticipated use, and care setting

9 evidence topics · 10 sources

Summary: anticipated place in treatment and care setting

Radical cystectomy is the guideline standard for BCG-unresponsive disease; the EAU 2026 guideline recommends offering it and recommends bladder preservation strategies, preferably within clinical trials, for patients who are not candidates for cystectomy or who decline it. BOND-003 enrolled participants who were medically unfit for cystectomy or who refused it, and the FDA draft guidance states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”. CG Oncology states that only approximately 6% of patients with NMIBC elect cystectomy, and another publication reports real-world rates of radical cystectomy for NMIBC below 20%.

The anticipated first use is in BCG-unresponsive high-risk NMIBC with carcinoma in situ, with or without papillary tumors. In its PIVOT-006 topline release, CG Oncology stated that, based on FDA feedback, the initial BLA will be broadened to include both carcinoma in situ and high-grade papillary-only disease, with completion anticipated in March 2027. Cretostimogene would enter a setting in which the FDA has approved pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln with BCG, and TAR-200 for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1.

The expected care setting is the urology office. BOND-003 Cohort C was run at 41 community and academic centres. Cretostimogene is instilled through a soft catheter without anesthesia or operating room time, and the company states that a medical assistant or nurse can prepare and administer it. The product is handled under biosafety level 2 precautions, described as “BSL-2 like BCG”, with protective equipment during preparation and administration. CG Oncology describes a field organization directed at community and academic urology networks.